Tuesday 5 November 2024

The Pharma Letter Podcast — Episode 27 — How to develop cancer drugs faster, with Ellipses Pharma

Biotechnology
Simon Wentworth
23 January 2024
episode-27-big

More on this story...

Pharmaceutical
The trust complex - strengthening the fundamentals of communications is more important than ever
8 February 2024
Pharmaceutical
Growing J&J sales tempered by rising costs
23 January 2024
Pharmaceutical
Doubling down on deep customer insights to inform value demonstration
5 February 2024
Pharmaceutical
BRIEF—Trends shaping healthcare marketplace analyzed in report
2 February 2024


Companies featured in this story

More ones to watch >


Today's issue

Nektar sells its PEGylation reagent manufacturing business
Biotechnology
Nektar sells its PEGylation reagent manufacturing business
5 November 2024
Pharmaceutical
PharmaMar gets $10 million milestone from Janssen for Yondelis
5 November 2024
Pharmaceutical
Photocure’s Hexvix wins Chinese approval
5 November 2024
Pharmaceutical
Vertex ups guidance again as results exceed estimates
5 November 2024
Biotechnology
Transgene and ProBioGen join forces on cancer vaccines
5 November 2024
Biotechnology
Nxera Pharma and Antiverse partner on GPCRs
5 November 2024
Pharmaceutical
Positive results for Neurocrine’s Ingrezza in tardive dyskinesia
5 November 2024

Company Spotlight

A Denmark-headquartered company that currently has a pipeline of three independent endocrinology rare disease product candidates in clinical development and is advancing oncology as its second therapeutic area of focus.




More Features in Biotechnology

Nektar sells its PEGylation reagent manufacturing business
5 November 2024
Transgene and ProBioGen join forces on cancer vaccines
5 November 2024
Nxera Pharma and Antiverse partner on GPCRs
5 November 2024
Frits van Alphen gets Memo CDO job
4 November 2024


Copyright © The Pharma Letter 2024   |   Headless Content Management with Blaze